Commodore Capital’s VistaGen Therapeutics VTGN Stock Holding History

Commodore Capital’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,575,000	Closed	-$5.59M	–	42
2025 Q3	$5.59M	Hold	1,575,000	–	–	0.27%	36
2025 Q2	$3.15M	Hold	1,575,000	–	–	0.22%	32
2025 Q1	$3.94M	Hold	1,575,000	–	–	0.29%	30
2024 Q4	$4.65M	Hold	1,575,000	–	–	0.34%	28
2024 Q3	$4.74M	Hold	1,575,000	–	–	0.3%	35
2024 Q2	$5.48M	Hold	1,575,000	–	–	0.37%	31
2024 Q1	$8.32M	Hold	1,575,000	–	–	0.56%	32
2023 Q4	$8.1M	Hold	1,575,000	–	–	0.71%	27
2023 Q3	$8.25M	Buy	+1,575,000	New	+$6.99M	0.96%	25
2022 Q3	–	Sell	-434,969	Closed	-$11.5M	–	33
2022 Q2	$11.5M	Buy	434,969 +98,395	+29%	+$3.47M	2.43%	15
2022 Q1	$12.5M	Buy	336,574 +54,407	+19%	+$2.37M	2.8%	13
2021 Q4	$16.5M	Buy	282,167 +111,383	+65%	+$7.25M	3.82%	12
2021 Q3	$14M	Buy	170,784 +59,740	+54%	+$5.19M	3.7%	12
2021 Q2	$10.5M	Sell	111,044 -13,279	-11%	-$984K	3.66%	13
2021 Q1	$7.94M	Buy	124,323 +19,323	+18%	+$1.29M	3.16%	13
2020 Q4	$6.11M	Buy	+105,000	New	+$2.68M	3.32%	16

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Commodore Capital's VTGN Position: Q4 2025 in Review

Commodore Capital sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 1,575,000 shares — an estimated $5.59M sold.

Commodore Capital first reported a position in VTGN in Q4 2020 and held it in 16 quarters. The position peaked at $16.5M in Q4 2021. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

Commodore Capital reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
Commodore Capital sold 1,575,000 VistaGen Therapeutics shares in Q4 2025, an estimated $5.59M.
Commodore Capital first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 16 quarters.
Commodore Capital's VistaGen Therapeutics position peaked at $16.5M in Q4 2021.
55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Commodore Capital's 13F filing for Q4 2025, filed 17 Feb 2026.